Valuation for NEUP - findataslice

	Neuphoria Therapeutics Inc.
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date			2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024
Close Price of Common Stock	18.65$	11.53$	7.05$	5.71$	3.41$
Market Cap of Common Stock	43,969,482$	27,183,278$	13,253,732$	10,032,624$	11,985,886,966$
Market Cap of Common Stock QoQ%	61.75%	105.10%	32.11%	(99.92%)
Market Cap of Common Stock YoY%	(99.63%)
Common Shares Outstanding		2,357,613	1,978,460	1,853,966	1,628,659	3,117,662,864	1,103,954	995,913	891,115	855,042	1,468,735,424
Common Shares Outstanding QoQ%		19.16%	6.72%	13.83%	(99.95%)	282,308.77%	10.85%	11.76%	4.22%	(99.94%)
Common Shares Outstanding YoY%		(99.92%)	79.22%	86.16%	82.77%	364,521.02%	(99.93%)
Total Revenue TTM
Total Revenue			(13,267$)	15,000,000$	662,715$
Total Revenue QoQ%			(100.09%)	2,163.42%
Total Revenue YoY%
Gross Margin			100.00%	100.00%	100.00%
Earnings to Common Shareholders TTM			(369,632$)	5,826,999$	(8,213,310$)	(10,824,385$)	(15,492,166$)
Earnings to Common Shareholders			(8,883,657$)	11,262,161$	(1,943,349$)	(804,787$)	(2,687,026$)	(2,778,148$)	(4,554,424$)	(5,472,568$)
Earnings to Common Shareholders QoQ%			(178.88%)	679.52%	(141.47%)	70.05%	3.28%	39.00%	16.78%
Earnings to Common Shareholders YoY%			(230.61%)	505.38%	57.33%	85.29%
Profit Margin			66,960.56%	75.08%	(293.24%)
Equity to Common Shareholders			19,002,574$	25,997,308$	13,747,995$	17,070,364$	17,490,372$	17,945,737$	19,497,443$	17,227,512$	22,010,563$
Equity to Common Shareholders QoQ			(6,994,734$)	12,249,313$	(3,322,369$)	(420,008$)	(455,365$)	(1,551,706$)	2,269,931$	(4,783,051$)
Equity to Common Shareholders QoQ%			(26.91%)	89.10%	(19.46%)	(2.40%)	(2.54%)	(7.96%)	13.18%	(21.73%)
Equity to Common Shareholders YoY			1,512,202$	8,051,571$	(5,749,448$)	(157,148$)	(4,520,191$)
Equity to Common Shareholders YoY%			8.65%	44.87%	(29.49%)	(.91%)	(20.54%)
Dividends Paid
Additional Paid-In Capital QoQ			821,524$	1,182,967$	(90,603$)	(200,591$)
Treasury Stock
Treasury Stock QoQ
Price to Sales
Price to Earnings	-	-	-	1.72x	-
Price to Book	2.31x	1.43x	.70x	.39x	871.83x
Goodwill			8,638,609$	8,451,038$	8,407,271$	8,903,988$	8,690,018$	8,626,104$	8,840,075$	8,574,696$	8,694,186$
Goodwill QoQ%			2.22%	.52%	(5.58%)	2.46%	.74%	(2.42%)	3.10%	(1.37%)
Goodwill YoY%			(.59%)	(2.03%)	(4.90%)	3.84%	(.05%)
Other Intangible Assets			4,804,791$	4,970,474$	5,136,157$	5,301,839$	5,467,522$				6,130,253$
Other Intangible Assets QoQ			(165,683$)	(165,683$)	(165,682$)	(165,683$)
Amortization of Intangible Assets
Forward Price to Sales MRQ	-	-	-	.17x	4,521.51x
Forward Price to Earnings MRQ	-	-	-	.22x	-
Total Assets			28,589,614$	30,713,319$	18,168,220$	22,917,207$	27,649,093$				28,562,948$
Total Assets QoQ			(2,123,705$)	12,545,099$	(4,748,987$)	(4,731,886$)
Total Assets YoY			940,521$				(913,855$)
Total Liabilities			9,587,040$	4,716,011$	4,420,225$	5,846,843$	10,158,721$				6,552,385$
Total Liabilities QoQ			4,871,029$	295,786$	(1,426,618$)	(4,311,878$)
Total Liabilities YoY			(571,681$)				3,606,336$
Current Ratio			3.56x	11.01x	2.06x	3.30x	3.45x				4.87x
Total Current Assets			15,040,831$	17,090,239$	4,398,608$	8,429,478$	13,193,758$				13,326,612$
Total Current Assets QoQ			(2,049,408$)	12,691,631$	(4,030,870$)	(4,764,280$)
Total Current Liabilities			4,220,760$	1,552,063$	2,133,674$	2,551,713$	3,829,073$				2,738,788$
Total Current Liabilities QoQ			2,668,697$	(581,611$)	(418,039$)	(1,277,360$)
Debt to Asset Ratio			.34x	.15x	.24x	.26x	.37x				.23x
Long Term Debt
Long Term Debt QoQ
Long Term Debt YoY
Capital Lease Obligations			116,314$	141,060$	168,310$	219,350$	239,618$				353,765$
Interest Expenses
Cash and Cash Equivalents			14,210,745$	17,044,750$	4,344,578$	8,082,410$	12,608,109$	8,426,061$	10,154,961$	8,135,059$	12,103,047$
Cash and Cash Equivalents QoQ			(2,834,005$)	12,700,172$	(3,737,832$)	(4,525,699$)	4,182,048$	(1,728,900$)	2,019,902$	(3,967,988$)
Cash and Cash Equivalents YoY			1,602,636$	8,618,689$	(5,810,383$)	(52,649$)	505,062$
Interest Income			87,046$	12,741$	30,615$	36,096$	26,327$	52,615$	54,716$	86,439$